User profiles for Sylvia Plevritis
Sylvia K. PlevritisProfessor of Biomedical Data Science, Stanford University Verified email at stanford.edu Cited by 23536 |
The prognostic landscape of genes and infiltrating immune cells across human cancers
…, CD Hoang, M Diehn, RB West, SK Plevritis… - Nature medicine, 2015 - nature.com
Molecular profiles of tumors and tumor-associated cells hold great promise as biomarkers of
clinical outcomes. However, existing data sets are fragmented and difficult to analyze …
clinical outcomes. However, existing data sets are fragmented and difficult to analyze …
[HTML][HTML] Effect of screening and adjuvant therapy on mortality from breast cancer
DA Berry, KA Cronin, SK Plevritis… - … England Journal of …, 2005 - Mass Medical Soc
Background We used modeling techniques to assess the relative and absolute
contributions of screening mammography and adjuvant treatment to the reduction in breast-cancer …
contributions of screening mammography and adjuvant treatment to the reduction in breast-cancer …
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum
…, A Trejo, OI Ornatsky, RS Balderas, SK Plevritis… - Science, 2011 - science.org
Flow cytometry is an essential tool for dissecting the functional complexity of hematopoiesis.
We used single-cell “mass cytometry” to examine healthy human bone marrow, measuring …
We used single-cell “mass cytometry” to examine healthy human bone marrow, measuring …
Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE
The ability to analyze multiple single-cell parameters is critical for understanding cellular
heterogeneity. Despite recent advances in measurement technology, methods for analyzing …
heterogeneity. Despite recent advances in measurement technology, methods for analyzing …
Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation
…, I Sanchez-Garcia, SK Plevritis… - Proceedings of the …, 2015 - National Acad Sciences
Follicular lymphoma (FL) is incurable with conventional therapies and has a clinical course
typified by multiple relapses after therapy. These tumors are genetically characterized by B-…
typified by multiple relapses after therapy. These tumors are genetically characterized by B-…
Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA
…, JB Sunwoo, GP Nolan, EG Engleman, SK Plevritis - Nature …, 2022 - nature.com
Advances in multiplexed in situ imaging are revealing important insights in spatial biology.
However, cell type identification remains a major challenge in imaging analysis, with most …
However, cell type identification remains a major challenge in imaging analysis, with most …
Non–small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data—methods and preliminary results
Purpose To identify prognostic imaging biomarkers in non–small cell lung cancer (NSCLC)
by means of a radiogenomics strategy that integrates gene expression and medical images …
by means of a radiogenomics strategy that integrates gene expression and medical images …
Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture
…, J Wilhelmy, S Robine, LD Attardi, SK Plevritis… - Nature medicine, 2014 - nature.com
The application of primary organoid cultures containing epithelial and mesenchymal elements
to cancer modeling holds promise for combining the accurate multilineage differentiation …
to cancer modeling holds promise for combining the accurate multilineage differentiation …
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms
… Plevritis, principal investigator). Drs. Mandelblatt and Cronin were the writing and
coordinating committee for the project; all other collaborators are listed in alphabetical order. …
coordinating committee for the project; all other collaborators are listed in alphabetical order. …
[HTML][HTML] Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …